Want to see JP:4512 full AI Analyst Report?
Total Valuation
Wakamoto Pharmaceutical Co., Ltd. has a market cap or net worth of ¥9.72B. The enterprise value is ¥7.24B.
Market Cap¥9.72B
Enterprise Value¥7.24B
Share Statistics
Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,838,326
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Wakamoto Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 1.63%.
Return on Equity (ROE)0.02
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)1.63%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee32.70M
Profits Per Employee749.88K
Employee Count303
Asset Turnover0.60
Inventory Turnover1.32
Valuation Ratios
The current PE Ratio of Wakamoto Pharmaceutical Co., Ltd. is 44.4. Wakamoto Pharmaceutical Co., Ltd.’s PEG ratio is 0.21.
PE Ratio44.4
PS Ratio1.23
PB Ratio1.01
Price to Fair Value1.01
Price to FCF-11.59
Price to Operating Cash Flow0.00
PEG Ratio0.21
Income Statement
In the last 12 months, Wakamoto Pharmaceutical Co., Ltd. had revenue of 9.91B and earned 227.22M in profits. Earnings per share was 6.55.
Revenue9.91B
Gross Profit4.73B
Operating Income255.54M
Pretax Income256.40M
Net Income227.22M
EBITDA701.22M
Earnings Per Share (EPS)6.55
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Wakamoto Pharmaceutical Co., Ltd. pays an annual dividend of ¥3.5, resulting in a dividend yield of 1.06%
Dividend Per Share¥3.5
Dividend Yield1.06%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-2.96%
50-Day Moving Average280.04
200-Day Moving Average300.89
Relative Strength Index (RSI)58.68
Average Volume (3m)65.94K
Important Dates
Wakamoto Pharmaceutical Co., Ltd. upcoming earnings date is Aug 5, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Wakamoto Pharmaceutical Co., Ltd. as a current ratio of 3.48, with Debt / Equity ratio of 3.33%
Current Ratio3.48
Quick Ratio2.07
Debt to Market Cap0.03
Net Debt to EBITDA-2.29
Interest Coverage Ratio134.85
Taxes
In the past 12 months, Wakamoto Pharmaceutical Co., Ltd. has paid 29.18M in taxes.
Income Tax29.18M
Effective Tax Rate0.11
Enterprise Valuation
Wakamoto Pharmaceutical Co., Ltd. EV to EBITDA ratio is 15.08, with an EV/FCF ratio of -10.06.
EV to Sales1.07
EV to EBITDA15.08
EV to Free Cash Flow-10.06
EV to Operating Cash Flow-21.72
Balance Sheet
Wakamoto Pharmaceutical Co., Ltd. has ¥3.56B in cash and marketable securities with ¥100.00M in debt, giving a net cash position of ¥3.46B billion.
Cash & Marketable Securities¥3.56B
Total Debt¥100.00M
Net Cash¥3.46B
Net Cash Per Share¥99.33
Tangible Book Value Per Share¥339.05
Margins
Gross margin is 47.75%, with operating margin of 2.58%, and net profit margin of 2.29%.
Gross Margin47.75%
Operating Margin2.58%
Pretax Margin2.59%
Net Profit Margin2.29%
EBITDA Margin7.08%
EBIT Margin2.61%
Analyst Forecast
The average price target for Wakamoto Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast27.18%
EPS Growth Forecast252.59%